A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Romidepsin (Primary)
- Indications T cell lymphoma
- Focus Adverse reactions
- 28 Nov 2017 Planned End Date changed from 1 Jun 2021 to 1 Nov 2020.
- 28 Nov 2017 Planned primary completion date changed from 1 Jun 2020 to 1 Nov 2020.
- 28 Nov 2017 Status changed from not yet recruiting to recruiting.